Abstract: A suspension system for a cab of an off-road vehicle includes a superstructure configured to receive a cab frame. The superstructure forms a framework, the corners of which receive suspension assemblies and dampers. The suspension assemblies include one or more springs or resilient elements to resist suspension motion, and the dampers provide dampening of the motion. Lateral and longitudinal suspension motions are resisted by links between the corners of the superstructure. An anti-roll bar reduces roll. The entire suspension system may be pre-assembled and then joined to the vehicle chassis frame. The cab frame may then be placed on the suspension system. Parts of the suspension system may interface with and be housed by roll-over protective structures.

Abstract: A work vehicle comprises an internal combustion engine and a catalytic converter coupled to the exhaust of the engine. A reduction agent system provides for injection of a reduction agent, such as urea, upstream of the catalytic converter. Coolant heated by the engine is directed to the reduction agent system to defrost/heat the reduction agent, and is also directed to a vehicle cabin heating system. Flow of coolant may be preferentially directed to the cabin heating system rather than to the reduction agent system, such as following vehicle startup, particularly during cold-weather operation. Flow may be altered to favor the reduction agent system, such as based upon time and/or the temperature of the cabin.

Abstract: The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.

Abstract: The invention provides a pharmaceutically elegant solid oral formulation of olanzapine and a process for making such formulation.

Abstract: The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.

Abstract: The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation or olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.

Abstract: The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates thereof.

Abstract: The invention provides lower alcohol solvates of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno?2,3-b!?1,5!benzodiazepine (olanzapine) and a process for making such lower alcohol solvates of olanzapine. The invention provides a method for using such solvates of olanzapine to prepare substantially pure anhydrous Form I 2-methyl-thieno-benzodiazepine.

Abstract: The invention provides lower alcohol solvates of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine (olanzapine) and a process for making such lower alcohol solyates of olanzapine. The invention provides a method for using such solyates of olanzapine to prepare substantially pure anhydrous Form I 2-methyl-thieno-benzodiazepine.

Abstract: An improved process for preparing trialkylsilyl ester and acid halide derivatives of carboxylic acids is provided along with novel trialkylsilyl ester intermediates of 2-(2-furyl)-2-methoximinoacetic acid.

Abstract: An improved process for preparing trialkylsilyl ester and acid halide derivatives of carboxylic acids is provided along with novel trialkylsilyl ester intermediates of 2-(2-furyl)-2-methoximinoacetic acid.

Abstract: A process for preparing certain substituted benzyl esters of phenylacetic acids by esterification in a solvent in which the salt of the acid is insoluble, and in the presence of a phase transfer catalyst.

Abstract: Cephalosporin sulfoxides are reduced to the corresponding cephalosporins in the presence of a halogen scavenger with triaryl phosphite-halogen complexes derived from the kinetically controlled reaction of selected triaryl phosphites and chlorine or bromine.